title: Serum procollagen III peptide levels in subjects with sarcoidosis. A 5-year follow-up study.
abstract: In a prospective study, Type III procollagen N-terminal peptide was measured in the sera of 38 subjects with biopsy-proven pulmonary sarcoidosis at 6-month intervals over a period of 5 yr. The subjects were divided into four groups according to their radiologic presentation and clinical course: Group A (n = 10) subjects with sarcoidosis Type I without radiologic progression over 5 yr; Group B (n = 5) subjects with sarcoidosis Type I with radiologic progression to Stage II or III; Group C (n = 9) subjects with sarcoidosis Types II and III without progression over 5 yr; and Group D (n = 14) subjects with sarcoidosis Types II and III with radiologic progression. Lung function tests (FVC, FEV1, and DLCO), chest roentgenograms, and measurements of serum angiotensin converting enzyme (S-ACE) were performed concurrently with the S-PCP-III levels. Significantly higher levels of S-PCP-III were found in group B (Type I, progressive) (18.2 +/- 1.09 ng/ml) and in group D (Type II/III, progressive) (13.9 +/- 1.2 ng/ml) compared with those of Group A (Type I, stable) (9.1 +/- 1.09 ng/ml) and Group C (Type II/III, stable) (7.6 +/- 1.1 ng/ml) or normal volunteers (9.4 +/- 4 ng/ml) (p less than 0.001 for all comparisons). Changes in S-PCP-III levels tended to parallel the clinical course, and steroid treatment resulted in a significant decrease in S-PCP-III concentrations (p less than 0.001). In contrast, serum angiotensin converting enzyme (S-ACE) levels did not correlate with either the clinical course or radiologic changes.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Second Medical Department, Wilhelminenspital, Vienna, Austria.
authors.forename: W R
authors.initials: WR
authors.lastname: Pohl
authors.forename: A B
authors.initials: AB
authors.lastname: Thompson
authors.forename: H
authors.initials: H
authors.lastname: Köhn
authors.forename: S
authors.initials: S
authors.lastname: Losch
authors.forename: H
authors.initials: H
authors.lastname: Umek
authors.forename: E
authors.initials: E
authors.lastname: Legenstein
authors.forename: F
authors.initials: F
authors.lastname: Kummer
authors.forename: S I
authors.initials: SI
authors.lastname: Rennard
authors.forename: H
authors.initials: H
authors.lastname: Klech
mesh_terms: D000328:Adult; D001991:Bronchitis / Q000097:blood; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume; D006801:Humans; D008171:Lung Diseases / Q000097:blood* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood*; D007703:Peptidyl-Dipeptidase A / Q000097:blood; D011347:Procollagen / Q000097:blood*; D011446:Prospective Studies; D012008:Recurrence; D012507:Sarcoidosis / Q000097:blood* / Q000473:pathology / Q000503:physiopathology; D014797:Vital Capacity
chemical_list: D010446:Peptide Fragments; D011347:Procollagen; C041876:procollagen Type III-N-terminal peptide; D007703:Peptidyl-Dipeptidase A